NASDAQ$TNYA
Tenaya Therapeutics Inc · Q1 2022 earnings
Q1 2022 earnings · · Investor relations
Briefing
Reported financial results for the first quarter ended March 31, 2022 and provided business and program updates.
Tenaya Therapeutics reported its first quarter 2022 financial results, with a net loss of $31.1 million, or $0.75 per share. The company's cash, cash equivalents and investments totaled $213.5 million as of March 31, 2022, expected to fund operations into the second half of 2023. Tenaya continues to advance its pipeline, including TN-201 which received Orphan Medicinal Product designation from the European Commission.
- TN-201 received Orphan Medicinal Product designation from the European Commission for the treatment of HCM due to mutations in the MYBPC3 gene.
- Preclinical data for TN-401 was presented at Heart Rhythm 2022, showing restoration of heart function and increased survival in a Pkp2 knockout mouse model.
- IND-enabling efforts for TN-201 and TN-301 are on track, with IND applications expected to be submitted to the FDA in the second half of 2022.
- Tenaya expects its cGMP manufacturing facility in Union City, California, to become operational in the first half of 2022.
Headline financials
Revenue & EPS history
Tenaya Therapeutics · Revenue · Quarterly
$225K
Forward guidance
Tenaya expects to submit IND applications for TN-201 and TN-301 to the FDA in the second half of 2022, and for TN-401 in 2023. The company also anticipates its cGMP manufacturing facility will become operational in the first half of 2022 and believes its current cash, cash equivalents and investments will be sufficient to fund operations at least into the second half of 2023.
Tailwinds
- IND-enabling efforts for TN-201 and TN-301 are on track, with IND applications expected to be submitted to the FDA in the second half of 2022.
- Tenaya expects to submit an IND application for TN-401 to the FDA in 2023.
- Tenaya expects its state-of-the-art, modular cGMP manufacturing facility in Union City, California, will become operational in the first half of 2022.
- Current cash, cash equivalents and investments in marketable securities are expected to be sufficient to fund its current operating plan at least into the second half of 2023.
- TN-201 received Orphan Medicinal Product designation from the European Commission.
Headwinds
- The process of discovering, developing and commercializing drugs involves risks and uncertainties.
- Tenaya's ability to develop, initiate or complete preclinical studies and clinical trials, and obtain approvals for its product candidates is subject to risks.
- The timing, progress and results of preclinical studies for TN-201, TN-301, TN-401 and Tenaya’s other programs are subject to uncertainty.
- Tenaya’s ability to raise any additional funding it will need to continue to pursue its business and product development plans is uncertain.
- The potential for any clinical trial results to differ from preclinical, interim, preliminary, topline or expected results exists.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 17 quarterly earnings reports · overlaid with Q1 2022
+2.8%
Avg return
Earnings day
+2.1%
Avg return
5 days after
-5.6%
Avg return
30 days after
50%
9 / 18 earnings
Positive
+39.8%
Q3 2022
Best reaction
-18.7%
Q4 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +4.8% | +30.3% | -4.2% | |
| Q4 2025 | -1.3% | -0.2% | -19.7% | |
| Q3 2025 | -1.4% | -7.0% | -4.9% | |
| Q1 2025 | +7.8% | -3.3% | +38.2% | |
| Q4 2024 | -6.5% | -12.7% | -38.4% | |
| Q3 2024 | +17.4% | +20.7% | +68.1% | |
| Q1 2024 | -0.7% | +8.9% | -12.6% | |
| Q4 2023 | -8.9% | -5.1% | -13.6% | |
| Q3 2023 | -7.8% | -10.2% | -2.9% | |
| Q2 2023 | +7.3% | +0.0% | -24.6% | |
| Q1 2023 | +12.1% | +7.2% | +9.0% | |
| Q4 2022 | -18.7% | -20.6% | -25.9% | |
| Q3 2022 | +39.8% | +53.4% | +11.0% | |
| Q2 2022 | +1.5% | +6.5% | -11.3% | |
| Q1 2022 | -5.7% | -6.7% | -29.9% | |
| Q4 2021 | +6.0% | +3.2% | -5.0% | |
| Q3 2021 | +7.7% | -13.5% | -28.1% | |
| Q2 2021 | -2.8% | -12.6% | -6.5% | |
| Q1 2021 | — | — | — | |
| Q4 2020 | — | — | — | |
| Q3 2020 | — | — | — | |
| Q2 2020 | — | — | — | |
| Q1 2020 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro